Page 15 - கோர் ஒன்று ஆய்வகங்கள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vocan, eine Tochtergesellschaft von Core One Labs, wird mit dem früheren CEO von Canopy, Marcelo Galvão, zusammenarbeiten, um biosynthetisches Psilocybin in Brasilien zu lizenzieren

Vocan, eine Tochtergesellschaft von Core One Labs, wird mit dem früheren CEO von Canopy, Marcelo Galvão, zusammenarbeiten, um biosynthetisches Psilocybin in Brasilien zu lizenzieren
mittelstandcafe.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mittelstandcafe.de Daily Mail and Mail on Sunday newspapers.

United statesBritish columbiaMalu dreyerJoel shackerCompany in the fieldDevelopment of productsDevelopment in connectionTechnology of coreBoard of directors vocan biotechnologies incPartnerships for developmentBrazilian companyPartnership isCore one labs incCompany hasCompanies in the fieldHealth canada

Core One Labs Subsidiary Vocan to Work with Former Canopy CEO Mr Marcelo Galvao to License Bioynthesized Psilocybin in Brazil

Core One Labs Subsidiary Vocan to Work with Former Canopy CEO Mr Marcelo Galvao to License Bioynthesized Psilocybin in Brazil
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.

United statesBritish columbiaMarcelo galvJoel shackerVocan brazil biotechnologies incCore one labs incVocan biotechnologies incHealth canadaBoards of directors vocan biotechnologies incCanadian securities exchangeCore one labsVocan biotechnologiesVocan brazil biotechnologiesVocan brazilVocan brazilCanopy growth brazil

Core One Labs Inc : Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin

Core One Labs Inc.: Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin VANCOUVER, BC / ACCESSWIRE / February 26, 2021 / Core One Labs Inc. (CSE:COOL), (OTC PINK:CLABF), (Frankfurt:LD62, WKN: A2P8K3) (the Company or Core One ) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials. The Company s wholly owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has successfully completed the development of its psilocybin detection and quantification methodology. This significant achievement allows the Company to commence production trials with its first psilocybin producer strain.

United kingdomBritish columbiaJoel shackerCompany or core oneCore one labs incVocan biotechnologies incHealth canadaCanadian securities exchangeCore one labsVocan biotechnologiesCore oneOne labsDisclaimer statementControlled drugsSubstances actஒன்றுபட்டது கிஂக்டம்

Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin

Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaJoel shackerCompany or core oneCore one labs incVocan biotechnologies incHealth canadaCanadian securities exchangeCore one labsCore oneVocan biotechnologiesOne labsDisclaimer statementControlled drugsSubstances actஒன்றுபட்டது கிஂக்டம்

Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin

Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaJoel shackerCompany or core oneCore one labs incVocan biotechnologies incHealth canadaCanadian securities exchangeCore one labsCore oneVocan biotechnologiesCore oneOne labsDisclaimer statementControlled drugsSubstances act